JGC
ARLZ

J. Goldman & Co’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

J. Goldman & Co’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-45,000
Closed -$198K – 478
2016
Q4 		$198K Buy
+45,000
New +$214K 0.01% 280

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

J. Goldman & Co's ARLZ Position: Q1 2017 in Review

J. Goldman & Co sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q1 2017, closing a stake of 45,000 shares — an estimated $198K sold.

J. Goldman & Co first reported a position in ARLZ in Q4 2016 and held it in 1 quarter. The position peaked at $198K in Q4 2016. 78 funds tracked by Wall St. Rank hold ARLZ as of Q1 2017.

  • J. Goldman & Co reported no remaining Aralez Pharmaceuticals Inc. position as of Q1 2017 after selling out during the quarter.
  • J. Goldman & Co sold 45,000 Aralez Pharmaceuticals Inc. shares in Q1 2017, an estimated $198K.
  • J. Goldman & Co first reported a position in Aralez Pharmaceuticals Inc. in Q4 2016 and held it in 1 quarter.
  • J. Goldman & Co's Aralez Pharmaceuticals Inc. position peaked at $198K in Q4 2016.
  • 78 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q1 2017.

Based on J. Goldman & Co's 13F filing for Q1 2017, filed 15 May 2017.